Synthesis, Docking and Evaluation of Novel Pyrazole Carboxamide Derivatives as Multifunctional Anti-Alzheimer’s Agents

Ajmer Singh Grewal¹, Suneel Kumar Sharma¹, Deepti Pandita², Viney Lather¹*

¹Department of Pharmaceutical Chemistry, JCDM College of Pharmacy, Sirsa, 125055, Haryana, India
²Department of Pharmaceutics, JCDM College of Pharmacy, Sirsa, 125055, Haryana, India

*Corresponding authors: Viney Lather, Department of Pharmaceutical Chemistry, JCDM College of Pharmacy, Sirsa-125055, Haryana, India; Tel: +91-1666-238114; E-mail: vinnylather@gmail.com

Abstract
Alzheimer’s disease (AD) is a major public health problem. The dual inhibitors of monoamine oxidase-B (MAO-B) and acetyl cholinesterase (AchE) are reported as effective in treatment of AD. The present research work was planned to design, synthesize and evaluate pyrazole carboxamide derivatives as multifunctional agents for treatment of AD. A series of substituted pyrazole derivatives were synthesized by refluxing chalcone derivatives with substituted semicarbazides and evaluated by in silico docking studies to determine the binding interactions for the best fit conformations in the binding site of MAO-B protein. The selected compounds from the in silico studies were evaluated further for their cognition enhancing and AchE inhibitory activity. Compounds 8 and 11 significantly reversed the scopolamine induced amnesia on elevated plus maze (EPM) model and compound 8 was found to be most potent. The selected compounds also significantly reduced AchE activity in brain. These newly designed molecules could act as starting hits for the development of effective and potent multifunctional agents for the potential treatment of AD.

Keywords: Acetyl cholinesterase inhibitors; Alzheimer; Anti-Alzheimer’s activity; MAO-B inhibitors; Pyrazoles

Introduction
Alzheimer’s disease (AD), the most common form of dementia in elderly people, is a complex age-dependent neurodegenerative disorder of the central nervous system, characterized by progressive impairment in memory, cognitive functions, and behavioral disturbances[1]. The incidence of AD is increasing dramatically worldwide, largely due to amnesia. Various molecular studies suggest that AD has multiple etiologies, including genetic mutations, susceptible genes and environmental factors that promote formation and accumulation of insoluble amyloid-β and hyper-phosphorylated tau[2]. Patients with AD have a deficiency of cholinergic neurons in the central nervous system. Acetylcholinesterase (AChE) controls acetylcholine to proper levels by degradation; accordingly, excessive AChE activity leads to constant acetylcholine deficiency, memory, and cognitive impairments. This observation led to the development of AChE inhibitors as possible therapy for the loss of cognitive function[3,4]. Another potential therapy for AD is the use of monoamine oxidase-B (MAO-B) inhibitors, as MAO-B type activity is increased in patients with AD[5]. There are different recognized mechanisms by which MAO-B inhibitors could prevent neurodegeneration. First, they may decrease the free radical formation, which cause membrane and DNA destruction, from normal metabolism of the biogenic amines by inhibition of MAO-B in the central nervous systems. Second, they exhibit protective effects against neuronal apoptosis in cell culture. Third, MAO-B inhibitors were shown to reduce the secretion of neurotoxic products[6-8]. The MAO-B inhibitory properties of 1,3,5-triphenyl-2-pyrazoline derivatives had been reported earlier[9-11]. These findings urged the scientists to synthesize various pyrazole derivatives as MAO-B inhibitors and a significant number of pyrazole derivatives were found to have MAO-B inhibitory activity comparable to or higher than the reference
Pyrazole derivatives as anti-alzheimer’s agents

Compounds. Some of the reported pyrazole derivatives were also found to inhibit the AChE.[12-15] Considering the facts that pyrazole derivatives are promising compounds for dual MAO-B and AChE inhibition, this research work has been planned to synthesize and evaluate some novel pyrazole carboxamide derivatives as multifunctional anti-AD agents.

Materials and Methods

All the chemicals were purchased from Spectrochem Ltd., Otto Chemie Pvt. Ltd., Molychem, Sigma Aldrich, etc. and were used as such for the experiments. Melting points were determined using Vego V-MD melting point apparatus.

1H-NMR spectra were recorded by Bruker Avance II 300 MHz NMR spectrometer using DMSO-d6 as solvent and are expressed in parts per million (δ, ppm) downfield from tetramethylsilane (internal standard). Infrared (IR) spectra were recorded by KBr disc method on a Shimadzu IR affinity FTIR spectrophotometer.

Synthesis of pyrazole derivatives

The chalcone derivatives were prepared by condensing 4-substituted acetophenones (0.01 mol) with furfural (0.01 mol) in methanol using 10% sodium hydroxide (10 ml) and stirred at 20 - 25 °C temperature maintained using ice water bath. The reaction mixture was kept at room temperature for 24 hrs followed by addition to ice cold water and acidification with hydrochloric acid. The precipitates were filtered and washed with cold water. The substituted semicarbazides were obtained by addition of a solution of isocyanates (0.05 mol) in benzene (65 ml) drop wise in small portions with cooling using ice and vigorous stirring to a solution of hydrazine hydrate (0.05 mol) in methanol (100 ml). After the reaction was concluded, the hydrazine-N, N’-dicarbomethylamide (side product) was removed by cold filtration and substituted semicarbazides were collected. A solution of hydrazine-N H-NMR (δ ppm, DMSO-d6): 1.21 (t, 1H, CH3), 3.38 - 3.39 (m, 1H of pyrazoline), 4.08 (q, 2H, CH2 of OC2H5), 6.30 (dd, 1H, CH of C2, C3 and C4 of furan-2-yl), 6.42 (dd, 1H, CH of C2, C3 and C4 of furan-2-yl, J = 2.5, 4.5 Hz), 7.55 - 7.57 (m, 2H, CH of C3 and C6 of C6H4OC2H5), 7.62 (s, 1H, CH of C4 of C6H5), 7.64 (m, 2H, CH of C3 and C5 of C6H5), 7.76 - 7.83 (m, 1H, CH of C3 and C4 of C6H5), 7.85 (dd, 1H, CH of C3 and C4 of C6H5), 8.03 (s, 1H, NH of NH-C=O).

5-(furan-2-yl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide (6): IR (KBr Pellets) ν cm⁻¹: 1674 (C=O str., amide), 3296 (N-H str., amide), 1545 (N-O str., nitro), 1334 (N-O str., nitro), 1670 (C=C, aromatic), 2924 (C-H, aromatic).
Pyrazole derivatives as anti-Alzheimer's agents

IR (KBr Pellets) 5-(furan-2-yl)-3-(4-ethoxyphenyl)-N-(propan-2-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide (10): IR (KBr Pellets) ν cm−1: 1668 (C=O str., amide), 3122 (N-H str., amide), 1249 (C-N str.), 1668 (C=C str., aromatic), 2858 (C-H str., alkanes), 17-H-NMR (δ ppm, DMSO-d6): 1.19 (t, 1H, CH3 of OC2H5), 2.34 - 2.36 (m, 1H of pyrazoline), 4.01 - 4.04 (m, 1H of pyrazoline), 0.60 (q, 2H, CH of CH3OC2H5), 6.93 - 6.95 (m, 2H, CH of C3 and C6 of C6H4OC2H5), 7.56 (dd, 1H, CH of C2 and C6 of C6H4OC2H5), 8.12 (s, 1H, NH of NH-C=O).

IR (KBr Pellets) ν cm−1: 1693 (C=O str., amide), 3280 (N-H str., amide), 1573 (N-H bend, amide), 1296 (C=N str., pyrazoline), 1573 (C=C str., aromatic), 2926 (C-H str., alkanes), 1076 (C-O str., ether).

IR (KBr Pellets) ν cm−1: 1694 (C=O str., amide), 3329 (N-H str., amide), 1573 (N-H bend, amide), 1296 (C=N str., pyrazolone), 1573 (C=C str., aromatic), 2929 (C-H str., aromatic), 1304 (N-O str., nitro).

IR (KBr Pellets) ν cm−1: 1645 (C=O str., amide), 3288 (N-H str., amide), 1573 (N-H bend, amide), 1296 (C=N str., pyrazoline), 1573 (C=C str., aromatic), 2926 (C-H str., aromatic), 1301 (C-N str., pyrazoline), 1573 (C=C str., aromatic), 2929 (C-H str., aromatic), 1304 (N-O str., nitro).

IR (KBr Pellets) ν cm−1: 1631 (C=O str., amide), 3288 (N-H str., amide), 1577 (N-H band, amide), 1296 (C=N str., pyrazoline), 1577 (C=C str., aromatic), 2929 (C-H str., aromatic), 1308 (N-O str., nitro).

IR (KBr Pellets) ν cm−1: 1641 (C=O str., amide), 3286 (N-H str., amide), 1570 (N-H bend, amide), 1301 (C-N str., pyrazoline), 1570 (C=C str., aromatic), 2927 (C-H str., aromatic), 1306 (N-O str., nitro), 1573 (N-O str., nitro).

IR (KBr Pellets) ν cm−1: 1660 (C=O str., amide), 3288 (N-H str., amide), 1573 (N-H bend, amide), 1298 (C=N str.), 1573 (C=C str., aromatic), 2927 (C-H str., aromatic), 3086 (C-H str., alkane), 1367 (N-O str., nitro), 1573 (N-O str., nitro).

IR (KBr Pellets) ν cm−1: 1651 (C=O str., amide), 3290 (N-H str., amide), 1575 (N-H bend, amide), 1296 (C=N str., pyrazoline), 1575 (C=C str., aromatic), 2926 (C-H str., aromatic), 1083 (C-F str.).

Molecular docking studies

Docking was carried out for the synthesized molecules in the binding site of MAO-B protein (PDB entry: 2V61) and AChE protein (PDB entry: 1EVE) using AutoDock Vina[19] and graphical user interface, AutoDock tools (ADT) installed on windows 7[17]. The geometries of the ligands were optimized by Open Babel using molecular mechanics force field[18]. The ligands were prepared for docking by using ADT by assigning the charges to all the atoms and storing them as PDBQT file. The PDB files of MAO-B and AChE were edited with the help of PyMOL, and α chain was removed along with the complexed inhibitor. All water molecules and interacting ions were removed (The PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC). The PDBQT file for the protein was generated with the help of ADT by addition of all polar hydrogen atoms followed by charge assignment to the macromolecule. The calculations of grid parameters were accomplished by the Grid tool in ADT. The grid parameter file possessing all the information about the size of grid, protein, ligand and geometry of search space was prepared and saved as ‘Conf.txt’. Accuracy of the docking protocol was determined by docking co-crystallized MAO-B ligand; 7-(3-chlorobenzyloxy)-4-(methylamino) methyl-coumarin into the active site of MAO-B and AChE ligand donepezil in the active site of AChE. The optimized ligand molecules in PDBQT format were docked in the active site of MAO-B and AChE with Auto Dock Vina. Docking runs were launched from the command line, followed by the generation and scoring of best nine poses, for each and every ligand using the scoring function. At

Lather V., et al.
Pyrazole derivatives as anti-alzheimer’s agents

the end of the docking, ligands with most favorable free energy of binding were selected. The protein-ligand interactions were further analyzed for the docked ligands by using PyMOL and best poses in the binding site were drawn.

**Biological evaluation**

**Animals:** Swiss male albino rats (25 - 30 g) were purchased from Animal House of Lalajpat Rai University of Veterinary and Animal Sciences, Hisar (India). Animals were housed in an alternating light and dark cycle of 12 hrs each. All the rats were fed with commercially available rat’s normal pellet diet and water ad libitum. The experimental protocol was approved by Institutional Animals Ethics Committee and Committee for the Purpose of Control and Supervision of Experiments on Animals (Approval No. JCDMCO/IAEC/07/15/26).

**Evaluation of antiamnesic and cognition enhancing activity:** Animals were divided into 8 groups with 6 animals in each group. The mice were pre-treated orally for 7 days with selected synthesized molecules (10 mg/kg) suspended in 0.5% CMC. Donepezil (5 mg/kg) and scopolamine (0.4 mg/kg) were dissolved in water for injection before administration. Scopolamine was administered 1 hr after the test drug and 30 min after donepezil administration. The control group was treated with vehicle (0.5% CMC suspension) only. EPM test was performed for the evaluation of antiamnesic and cognition enhancing activity by measuring TL. The fabricated plus maze used in the study, consisted of two opposite open arms, crossed with two enclosed arms of same dimensions. The arms were connected with a central square to give the apparatus a plus sign appearance. The maze was kept in dim light room at an elevated height on 7th day, 1 hr after the last dose of selected molecules, pre-treatment and 30 min after donepezil treatment, individual rats from each group were placed on the end of one of the open arms facing away from the centre. Time taken by the animal to enter one of the closed arms (TL considered as day 1) was recorded with the help of a stop watch. The rats were left in the enclosed arm for 10 - 15 s and returned to its home cage. On day 2, the same procedure was repeated and TL was recorded[3,19].

**Evaluation of AChE inhibitory activity:** For determination of AChE inhibitory activity of the selected molecules, rats were distributed into 6 groups (1 control+5 test compounds) with each having 6 rats. The control group received vehicle only. The rats were pretreated orally once with the selected molecules (10 mg/kg) for 7 days and on day 7, 1 hr after the last dose all rats were quickly killed using light ether anesthesia and brain was isolated from the skull immediately. Brain was homogenized in ice cold 0.1 M phosphate buffer (pH 8.0), centrifuged for 10 min at 4°C, and supernatant was mixed with phosphate buffer (pH 7.0) followed by addition of substrate acetyl thiocholine iodide and dithiobisnitrobenzoic acid reagent. Change in absorbance per minute of the sample was read at 412 nm using a spectrophotometer. The enzyme activity was expressed as the moles of substrate hydrolyzed/min/mg of protein[3].

**Results and Discussion**

**Chemistry**

The synthesis of designed pyrazole carboxamide derivatives was carried out as demonstrated in Figure 1. Chalcones were obtained by reacting furfural with 4-substituted acetophene derivatives in ice bath followed by refluxing with the substituted semicarbazides. The yield of synthesized compounds was appreciable and their physicochemical characteristics are presented in Table 1. The progress of reaction and purity of compounds was confirmed from the consistent spectral data.

**Figure 1:** Synthetic route for substituted pyrazole carboxamide derivatives.

**Table 1:** Physiochemical properties of synthesized pyrazole carboxamide derivatives.

| Compound | R<sup>1</sup> | R<sup>2</sup> | Mol. formula | M. Pt. (°C) | R<sub>*</sub> | % yield |
|----------|--------------|--------------|--------------|-------------|-----------|--------|
| 1        | -CH<sub>3</sub> | -C<sub>6</sub>H<sub>5</sub> | C<sub>18</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub> | 255 - 257 | 0.70 | 48 |
| 2        | -OCH<sub>3</sub> | -C<sub>6</sub>H<sub>5</sub> | C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub> | 220 - 225 | 0.76 | 54 |
| 3        | -OC<sub>2</sub>H<sub>5</sub> | -C<sub>6</sub>H<sub>5</sub> | C<sub>17</sub>H<sub>18</sub>ClN<sub>3</sub>H<sub>8</sub> | 240 - 242 | 0.30 | 45 |
| 4        | -Cl          | -C<sub>6</sub>H<sub>5</sub> | C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> | 180 - 190 | 0.47 | 65 |
| 5        | -Br          | -C<sub>6</sub>H<sub>5</sub> | C<sub>17</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>4</sub> | 200 - 202 | 0.51 | 57 |
| 6        | -F           | -C<sub>6</sub>H<sub>5</sub> | C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> | 230 - 232 | 0.57 | 40 |
| 7        | -NO<sub>2</sub> | -C<sub>6</sub>H<sub>5</sub> | C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> | 238 - 240 | 0.80 | 55 |
| 8        | -CH<sub>3</sub> | -CH(CH<sub>3</sub>)<sub>2</sub> | C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> | 210 - 212 | 0.66 | 57 |
Pyrazole derivatives as anti-Alzheimer’s agents

Lather V., et al.

9. -OCH₃ -CH(CH₃)₂ C₂₁H₁₉N₃O₃ 273 - 275 0.23 49
10. -OC₂H₅ -CH(CH₃)₂ C₂₁H₁₉N₃O₂ 255 - 257 0.67 45
11. -Cl -CH(CH₃)₂ C₂₁H₁₆FN₃O₂ 300 - 302 0.60 58
12. -F -CH(CH₃)₂ C₂₀H₁₆ClN₃O₃ 275 - 277 0.38 60
13. -NO₂ -CH(CH₃)₂ C₂₀H₁₆BrN₃O₃ 300 - 302 0.60 53
14. -Br -CH(CH₃)₂ C₂₀H₁₆N₄O₄ 270 - 272 0.22 60
15. -CH₃ -CH₂C₆H₅ C₂₁H₁₈N₄O₄ 270 - 272 0.70 60
16. -OCH₃ -CH₂C₆H₅ C₂₂H₂₁N₃O₄ 250 - 252 0.64 55
17. -OC₂H₅ -CH₂C₆H₅ C₂₂H₂₁N₃O₂ 255 - 257 0.43 65
18. -Cl -CH₂C₆H₅ C₂₂H₂₃N₃O₃ 258 - 260 0.69 53
19. -Br -CH₂C₆H₅ C₂₂H₂₃N₃O₂ 260 - 262 0.75 48
20. -NO₂ -CH₂C₆H₅ C₂₁H₁₈O₄ 260 - 262 0.46 59
21. -F -CH₂C₆H₅ C₂₁H₁₈BrN₃O₂ 280 - 282 0.67 66

*TLC mobile phase: n-hexane: ethyl acetate (7:3)

The 1H-NMR spectra of compounds showed the singlet signal equivalent to one proton of the -NHCO group around δ 10 ppm, thus confirming the formation of carboxamide bond in the synthesized molecules. The signal for the NH proton was observed at δ 2.5 ppm which confirmed the presence of pyrazoline ring by the reaction of chalcones derivatives and substituted semi-carbazides. The 1H-NMR spectra of compounds exhibited the presence of two equivalent protons to that of a methylene group (H₂/C₆H₅) at δ 3.00 - 3.40 ppm and 3.72 - 3.80 ppm coupled with each other and in turn with the vicinal methine proton (H-5) at δ 6.38 - 6.55 ppm. A doublet signal was observed at δ 6.30 - 6.45 ppm indicating the presence of furan-2-yl ring in the synthesized compounds. Multiplet signal in the range of δ 6.5 - 7.5 ppm showed the substitution at 4-postion of the phenyl ring. The protons belonging to the aromatic ring and the other aliphatic groups were observed with the expected chemical shift and integral values. The IR spectra of the compounds revealed absorption bands in the regions 1080 - 1300 cm⁻¹ corresponding to C=N stretching bands formed due to ring closure indicating the presence of pyrazoline ring in the synthesized compounds. C=O stretching (1820 - 1670 cm⁻¹), N-H stretching (3500 - 3100 cm⁻¹) and N-H bending (1640 - 1550 cm⁻¹) frequencies revealed the formation of carboxamide bond in the synthesized molecules.

Docking studies

Docking studies were performed to evaluate the affinity and binding interactions of synthesized molecules in active site of MAO-B (PDB entry: 2V61) and AChE (PDB entry: 1EVE) using Auto Dock vina and Auto Dock Tools. The docking protocol was evaluated by docking of the co-crystallized ligand into the active site of 2V61 and the resulting binding pose was compared with that of co-crystallized ligand. The ligand had a similar binding pattern and superposition to that of co-crystallized ligand, thus validating the docking protocol. All the designed compounds were docked in the active site of MAO-B protein and AChE. Amongst all the molecules, 4,8,11,17 and 20 had appreciable binding to the binding site as determined by analyzing the binding free energy (ΔG) and binding mode of the selected best docked poses (Table 2). On the basis of their lowest binding free energy and docking interaction in the binding site, compounds 4,8,11,17 and 20 were further analyzed in details by PyMOL. The overlay of the selected compounds with the PDB ligand 2V61 showed that the selected compounds had the similar binding pattern in the binding site of the protein as that of the co-crystallized ligand of 2V61 and thus has similar type of binding interactions (Figure 2 and 3). The overlay of the selected compounds with the PDB ligand 2V61 helped us in predicting that the synthesized pyrazole derivatives could act as strong MAO-B inhibitors.

| Compound | ΔG (kcal/mol) for MAO-B | ΔG (kcal/mol) for AchE | Mol. Wt. | Log P* | HBA* | HBD* |
|----------|-------------------------|------------------------|---------|-------|------|------|
| 1        | - 7.9                   | - 8.5                  | 311     | 4.38  | 2    | 1    |
| 2        | - 7.6                   | - 8.2                  | 315     | 3.71  | 3    | 1    |
| 3        | - 7.0                   | - 8.1                  | 331     | 4.07  | 3    | 1    |
| 4        | - 8.1                   | - 9.9                  | 342     | 4.47  | 2    | 1    |
| 5        | - 6.9                   | - 8.8                  | 376     | 4.64  | 2    | 1    |
| 6        | - 8.0                   | - 8.9                  | 327     | 4.01  | 2    | 1    |
| 7        | - 6.3                   | - 9.3                  | 341     | 3.81  | 4    | 1    |
| 8        | - 8.8                   | - 10.4                 | 375     | 3.14  | 2    | 1    |
| 9        | - 7.2                   | - 7.6                  | 361     | 2.47  | 3    | 1    |
| 10       | - 7.8                   | - 9.3                  | 345     | 2.82  | 3    | 1    |
| 11       | - 8.5                   | - 9.4                  | 349     | 3.23  | 2    | 1    |
| 12       | - 7.1                   | - 9.0                  | 365     | 2.77  | 2    | 1    |
Pyrazole derivatives as anti-alzheimer’s agents

|   |       |       |   |       |  
|---|-------|-------|---|-------|---|
| 13 | -8.1  | -8.1  | 410 | 2.56  | 4  |
| 14 | -8.4  | -9.8  | 376 | 3.39  | 2  |
| 15 | -7.9  | -10.4 | 390 | 4.09  | 2  |
| 16 | -7.0  | -10.1 | 359 | 3.42  | 3  |
| 17 | -8.5  | -9.9  | 375 | 3.77  | 3  |
| 18 | -7.2  | -8.9  | 389 | 4.18  | 3  |
| 19 | -7.6  | -9.5  | 379 | 4.34  | 2  |
| 20 | -8.1  | -9.2  | 363 | 3.52  | 4  |
| 21 | -6.9  | -9.8  | 424 | 3.72  | 2  |

*Log P, HBA, HBD, Mol. wt. were calculated by Marvin tools of Marvin Sketch v 5.5.

Figure 2: Docked pose for compounds 8 (a) and 11 (b) and PDB ligand of 2V61 in the binding site of MAO-B protein.

Figure 3: Docked pose for compounds 8 (a) and 11 (b) and PDB ligand of 1EVE (donepezil) in the binding site of AchE protein.

Evaluation of anti-AD activity

Based on the results of docking studies compounds 4, 8, 11, 17, and 20 were evaluated in vivo in rats for anti-AD using an EPM test taking donepezil as standard anti-AD drug. The time taken by the animal to enter one of the closed arms (transfer latency (TL), considered as day 1) was recorded with the help of a stop watch. The mouse was left in the enclosed arm for 10-15s and returned to its home cage. On day 8, i.e., second day of the EPM exposure, the same procedure was repeated and TL was recorded. The results of anti-AD activity measured as TL on day 1 and day 2 are presented in Table 3. The effect of the orally given selected compounds on changes in TL was analyzed by one-way ANOVA. Statistical analysis showed significant differences in TL among treatment groups (p < 0.001). The results of anti-AD activity indicated that compounds 8 and 11 were found to be highly active with compound 8 showing better potency than compound 11. Compound 8 was also found to be more potent than the standard drug do-
Pyrazole derivatives as anti-alzheimer’s agents

Table 3: Effect of orally administered compounds on cognition enhancing and scopolamine-induced amnesia.

| Treatment                  | Transfer latency (s) |
|---------------------------|----------------------|
|                           | Day 1                | Day 2                |
| 4                         | 57.76 ± 2.89         | 46.92 ± 4.17**       |
| 8                         | 33.52 ± 4.05         | 24.34 ± 3.17**       |
| 11                        | 39.24 ± 3.46         | 27.31 ± 2.50**       |
| 17                        | 64.28 ± 4.21         | 53.08 ± 3.57**       |
| 20                        | 64.75 ± 2.18         | 48.19 ± 4.45**       |
| Scopolamine alone         | 80.73 ± 1.54         | 94.54 ± 1.27*        |
| Vehicle only (control)    | 67.41 ± 3.43         | 57.53 ± 3.42         |
| Donepezil (Standard drug) | 41.51 ± 1.45         | 25.31 ± 1.24**       |

Data are expressed as mean ± SEM (n = 6). Data are statistically analyzed by one-way ANOVA; *Scopolamine treated groups are significantly different from control group p < 0.001 ** significantly different from scopolamine treated group p < 0.001.

Estimation of AChE inhibitory activity

The effects of selected compounds for AChE activity in brain are presented in Figure 4. The results showed significantly different AChE activity between the groups as determined by ANOVA. All the compounds significantly decreased the AChE activity in brain as compared to control. These results suggest that pyrazole derivatives due to their anti-AChE activity enhance cholinergic neurotransmission in brain and thus enhance learning and memory functions.

Figure 4: Effect of orally administered compounds on AChE activity in brain.

Conclusion

The present research work involved the design, synthesis and evaluation of some novel pyrazole derivatives considered to have dual inhibitors of MAO-B and AChE as anti-AD agents. In silico studies were performed for the synthesized molecules and compounds 4, 8, 11, 17, and 20 were selected for in vivo anti-AD. Molecules were evaluated for anti-AD activity by EPM test using donepezil as standard anti-AD drug. Amongst the synthesized substituted pyrazole derivatives, compounds 8 and 11 showed higher anti-AD activity. Compound 8 was found to be more potent than standard drug donepezil. The experimental results were found to be in concordance with that of the in silico results for MAO-B activity and all the synthesized molecules possessed drug like properties as devised by Lipinski rule of five. These new designed molecules could act as initial hit molecules for the design of effective and orally bioavailable dual inhibitors of MAO-B and AChE for the potential treatment of AD.

Acknowledgements: The authors are thankful to the Management, JCD Vidyapeeth, Sirsa (Haryana) for their support and encouragement for this research work.
Pyrazole derivatives as anti-Alzheimer’s agents

References

1. Bartus, R.T., Dean, R.L., Beer, B.e.t al. The cholinergic hypothesis of geriatric memory dysfunction. (1982) Science 217(4558): 408-414.
2. Yokel, R.A. The toxicology of aluminum in the brain: a review. (2000) Neurotoxicol 21(5): 813-828.
3. Sinha, S.K., Shrivastava, S.K. Synthesis and evaluation of some new 4-aminopyridine derivatives as a potent antiinamasic and cognition enhancling drugs. (2012) Med Chem Res 21(12): 4395-4402.
4. Yamada, N., Hattori, A., Hayashi, T. et al. Improvement of scopolamine-induced memory impairment by natural in the water maze in mice. (2004) Pharmacol Biochem Behav 78(4): 787-791.
5. Riederer, P., Danielczyk, W., Grunblatt, E. Monoamine oxidase-B inhibition in Alzheimer’s disease. (2004) Neurotoxicology 25(1-2): 271-277.
6. Cohen, G., Spina, M.B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. (1989) Ann Neurol 26(5): 689-690.
7. Suuronen, T., Kolehmainen, P., Salminen, A. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. (2000) Biochem Pharmacol 59(12): 1589-1595.
8. Klegcris, A., Me Geer, P.L. R(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monooamine oxidase inhibition. (2000) Exp Neurol 66(2): 458-464.
9. Parmar, S.S., Pandey, B.R., Dwivedi, C. et al. Anticonvulsant activity and monoamine oxidase inhibitory properties of 1,3,5-trisubstituted-pyrazolines. (1974) J Pharm Sci 63(7): 1152-1155.
10. Manna, F., Chimenti, F., Bolasco, A. et al. Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. (2002) Bioorg Med Chem Lett 12(24): 3629-3633.
11. Chimenti, F., Maccioni, E., Secci, D. et al. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diallyl-4,5-dihydro-(1H)-pyrazole derivatives. (2005) J Med Chem 48(23): 7113-7122.
12. Yeşilada, A., Gokhan, N., Ozer, I. et al. 5-methyl-8-N-substituted-thiocarbamoyl-7,8-diazabicyclo[4.3.0]non-6-ones: evaluation as BSAO inhibitors and pharmacological activity screening. (1996) Farmaco51(12): 775-781.
13. Gokhan, N., Yesilada, A., Ucar, G. et al. 1-N-substituted thioicarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation as MAO inhibitors. (2003) Arch Pharm 336(3): 362-371.
14. Ucar, G., Gokhan, N., Yesilada, A. et al. Interaction of some 1-N-substituted thioicarbamoyl-3-phenyl-5-thienyl-2-pyrazolines with rat liver semicarbazide-sensitive amine oxidase (SSAO). (2005) J Faculty Pharm 25(1): 23-34.
15. Ucar, G., Gokhan, N., Yesilada, A. et al. 1-N-Substituted thioicarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson’s and Alzheimer’s diseases. (2005) Neurosci Lett 382(3): 327-331.
16. Trott, O., Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. (2010) J Comput Chem 31(2): 455-461.
17. Morris, G.M., Huey, R., Lindstrom, W. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. (2009) J Comput Chem 30(16): 2785-2791.
18. O’Boyle, N.M., Banck, M., James, C.A. et al. Open Babel: an open chemical toolbox. (2011) J Cheminform 3: 33.
19. Ojha, R., Sahu, A.N., Muruganandam, A.V. et al. Asparagus reccemosus enhances memory and protects against amnesia in rodent models. (2010) Brain Cogn 74(1): 1-9.